Parexel
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
Corporate information
- Company entity
- Parexel
- Headquarters / principal office
- Raleigh, North Carolina, United States (current investor profile) ↗
- Founded
- 1982 ↗
- Ownership / capital status
- PrivatePrivate CRO backed by EQT and Goldman Sachs Asset Management ↗
- Official corporate reference
- https://www.parexel.com/solutions/integrated-clinical-development/quantitative-clinical-pharmacology-and-model-informed-drug-development ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Quantitative Clinical Pharmacology and Model-Informed Drug Development | Parexel
- Parexel — current EQT portfolio